Suda Pharmaceuticals Ltd EV / EBITDA
Was ist das EV / EBITDA von Suda Pharmaceuticals Ltd?
EV / EBITDA von Suda Pharmaceuticals Ltd ist N/A
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf ASX im Vergleich zu Suda Pharmaceuticals Ltd
Was macht Suda Pharmaceuticals Ltd?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Unternehmen mit ev / ebitda ähnlich Suda Pharmaceuticals Ltd
- C4X Discovery Plc hat EV / EBITDA von N/A
- Pacgen Life Science hat EV / EBITDA von N/A
- Panther Metals Plc hat EV / EBITDA von N/A
- InnovaDerma Plc hat EV / EBITDA von N/A
- CryptoStar hat EV / EBITDA von N/A
- CHAR Technologies hat EV / EBITDA von N/A
- Suda Pharmaceuticals Ltd hat EV / EBITDA von N/A
- Dixie Gold hat EV / EBITDA von N/A
- Novacyt S.A hat EV / EBITDA von N/A
- Bald Eagle Gold hat EV / EBITDA von N/A
- Pier 1 Imports Inc hat EV / EBITDA von N/A
- Element 29 Resources Inc hat EV / EBITDA von N/A
- Standard BioTools Inc hat EV / EBITDA von N/A